Virus Like Particles as Immunogens and Universal Nanocarriers

Naskalska, Antonina; Pyrć, Krzysztof

doi:10.33073/pjm-2015-001

Cited by 64 publications

(53 citation statements)

References 105 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although synthetically prepared nanoparticles have yet to show the level of ordered antigen arrangement found on viruses and virus-like particles derived from cell culture systems [181,182], ongoing studies continue to demonstrate emerging techniques to couple antigens of interest to nanocarriers. In the last section of the review, we review commonly used methods for coupling antigens with nanoparticles.…”

Section: Repetitive Antigen Display For Immune Activationmentioning

confidence: 99%

Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation

et al. 2017

View full text Add to dashboard Cite

Synthetic nanoparticles play an increasingly significant role in vaccine design and development as many nanoparticle vaccines show improved safety and efficacy over conventional formulations. These nanoformulations are structurally similar to viruses, which are nanoscale pathogenic organisms that have served as a key selective pressure driving the evolution of our immune system. As a result, mechanisms behind the benefits of nanoparticle vaccines can often find analogue to the interaction dynamics between the immune system and viruses. This review covers the advances in vaccine nanotechnology with a perspective on the advantages of virus mimicry towards immune potentiation. It provides an overview to the different types of nanomaterials utilized for nanoparticle vaccine development, including functionalization strategies that bestow nanoparticles with virus-like features. As understanding of human immunity and vaccine mechanisms continue to evolve, recognizing the fundamental semblance between synthetic nanoparticles and viruses may offer an explanation for the superiority of nanoparticle vaccines over conventional vaccines and may spur new design rationales for future vaccine research. These nanoformulations are poised to provide solutions towards pressing and emerging human diseases.

show abstract

Section: Repetitive Antigen Display For Immune Activationmentioning

confidence: 99%

Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Devoid of viral genetic material, VLPs do not replicate within the host cell, but can be used as carriers for nucleic acids, proteins or drugs. Numerous studies have demonstrated that VLPs originating from different viral species may be produced using eukaryotic expression systems (reviewed in [1][2][3]). Coronaviruses-enveloped, positive-stranded RNA viruses that cause common respiratory diseases in humans and a broad variety of diseases in animals are also able to form such structures.…”

Section: Introductionmentioning

confidence: 99%

Novel coronavirus-like particles targeting cells lining the respiratory tract

et al. 2018

Self Cite

View full text Add to dashboard Cite

Virus like particles (VLPs) produced by the expression of viral structural proteins can serve as versatile nanovectors or potential vaccine candidates. In this study we describe for the first time the generation of HCoV-NL63 VLPs using baculovirus system. Major structural proteins of HCoV-NL63 have been expressed in tagged or native form, and their assembly to form VLPs was evaluated. Additionally, a novel procedure for chromatography purification of HCoV-NL63 VLPs was developed. Interestingly, we show that these nanoparticles may deliver cargo and selectively transduce cells expressing the ACE2 protein such as ciliated cells of the respiratory tract. Production of a specific delivery vector is a major challenge for research concerning targeting molecules. The obtained results show that HCoV-NL63 VLPs may be efficiently produced, purified, modified and serve as a delivery platform. This study constitutes an important basis for further development of a promising viral vector displaying narrow tissue tropism.

show abstract

“…VLPs can stimulate robust humoral and cellular immunity responses via several mechanisms, including mimicking the structure and conformation of the native virus, possessing repetitive elements, and larger dimensions [12][13][14]. Given these unique characteristics, VLPs became interesting in vaccine design and development, employed as platforms presenting exogenous 4 antigens [13,15] and as carriers to deliver nucleic acids, drugs, and proteins [16].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis E virus truncated capsid protein as a potential carrier of exogenous antigens for the development of chimeric virus-like particle vaccines

Lu¹,

Behloul

Zhou³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Virus like particle (VLP), a multiprotein structure which is assembled automatically, can stimulate robust immune responses due to an appropriate size, repetitive epitopes, and a structure similar to native virions. Utilizing VLPs as vaccine carriers to present exogenous antigens is a promising and challenging field in vaccine design. Hence, this study aims to investigate the potential of Hepatitis E virus (HEV) truncated capsid protein as a VLP carrier presenting foreign antigens in vaccine design.Results: S and M domains of HEV ORF2 protein (aa112-455) were selected as an optimal carrier (CaSM). The exogenous antigen Seq8 containing three immunogenic domains from three different foot-and-mouth disease virus (FMDV) strains was linked to the C-terminal of CaSM to construct a chimeric VLP vaccine candidate (CaSM-Seq8). Morphological analysis showed that CaSM-Seq8 self-assembled into VLPs with a diameter of approximately 26 nm, similar to the VLPs of CaSM alone but smaller than native HEV virions. Further, the thermal stability and the proteolysis resistance of Seq8 were enhanced when carried by CaSM. The antigenicity analysis revealed a more robust reactivity against anti-FMDV specific antibodies when Seq8 was presented on the CaSM particles. Upon injection into mice, anti-FMDV IgGs induced by CaSM-Seq8 appeared earlier, increased faster, and maintained higher levels for a longer time than those induced by Seq8 antigen alone or a commercial inactivated FMDV vaccine.Conclusions: This study demonstrates the potential of the HEV truncated capsid protein VLPs as a presenting-platform of exogenous antigens in vaccine design and promising preliminary results on chimeric VLP vaccine against foot-and-mouth disease.

show abstract

Virus Like Particles as Immunogens and Universal Nanocarriers

Cited by 64 publications

References 105 publications

Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation

Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation

Novel coronavirus-like particles targeting cells lining the respiratory tract

Hepatitis E virus truncated capsid protein as a potential carrier of exogenous antigens for the development of chimeric virus-like particle vaccines

Contact Info

Product

Resources

About